Development of a First-in-Class αPD-1/αVEGF/IL-2v Triple-Action Immuno-Oncology Therapeutic for Refractory Solid Tumors

MustBio

ONCOLOGY **Lead**

Product Type	Recombinant Protein
Indication	Solid tumor
Target	PD-1, VEGF, and IL-2 receptor in activated T cells
MoA(Mechanism of Action)	The αPD-1/αVEGF/IL-2v tri-specific fusion protein continuously activates T cell via αPD-1, increases tumor-infiltrating lymphocytes (TILs) via αVEGF, and robustly activates and expands effector T cells through a novel IL-2v, ensuring potent anti-tumor efficacy with a favorable safety profile.
Competitiveness	• First-in-class αPD-1/αVEGF/IL-2v triple-action immuno-oncology therapeutic • Excellent anti-tumor efficacy beyond αPD-1 threapies in ICI resistant model • Wide safety margin in animal models
Development Stage	Lead
Route of Administration	Intravenous